Arcutis Biotherapeutics, Inc. (ARQT) — AI News Sentiment & Analysis

FDA target action date (PDUFA) for Supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05% for infants. (Timing: February 23, 2027)

FDA approval of ZORYVE (roflumilast) Cream 0.3% to treat plaque psoriasis in children aged 2 and older. (Timing: Immediate market impact, with revenue realization expected over the next several quarters as commercialization in the pediatric market scales.)

Continued strong commercial performance of ZORYVE, FDA sNDA decision for expanded indication in infants (target date June 29, 2026), and progression of new pipeline candidates (ARQ-234 Phase 1, ZORYVE foam MUSE trial results). (Timing: Ongoing commercial growth, June 2026 (FDA decision), Q4 2026 / Q1 2027 (Phase 2 results).)

Presentation of new efficacy, safety, and tolerability data from INTEGUMENT-INFANT Phase 2 trial and long-term data from INTEGUMENT-OLE Phase 3 trial for ZORYVE at the AAD Annual Meeting. (Timing: March 27-31, 2026)

Arcutis has begun enrolling participants in a Phase 1a/1b study for ARQ-234, a treatment for atopic dermatitis. This is important because it could lead to new options for patients suffering from this condition. The recent initiation of this clinical trial presents a potential buying opportunity as it may unlock value if the treatment proves effective.

The primary catalyst is the better-than-expected Q4 and full-year 2025 financial results, including positive net income and operating cash flow, coupled with raised 2026 net product sales guidance. Positive Phase 2 clinical data and regulatory progress for ZORYVE also contribute to the positive outlook. (Timing: The immediate catalyst is the market open following this after-hours announcement. Sustained impact is expected over the next few quarters as the company executes on its raised guidance and pipeline advancements.)